BioXcel Therapeutics (BTAI) Interest & Investment Income (2020 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Interest & Investment Income of $211000.0 for Q1 2026, down 24.37% year-over-year from $279000.0 in Q1 2025, and down 34.27% quarter-over-quarter from $321000.0 in Q4 2025.
BioXcel Therapeutics (BTAI) Interest & Investment Income (2020 - 2026) Analysis & Trends
BioXcel Therapeutics' Interest & Investment Income history runs 7 years deep, the most recent figure standing at $211000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 24.37% year-over-year to $211000.0; the TTM figure through Mar 2026 stood at $998000.0 (down 48.4% YoY), while the FY2025 annual figure was $1.1 million, down 59.03% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $211000.0, down from $321000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $2.0 million in Q1 2023, with the low at $15000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $616000.0 (2024), against an average of $709235.3.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income soared 13333.33% in 2023, then slumped 70.54% in 2025.
- BioXcel Therapeutics' Interest & Investment Income stood at $1.5 million in 2022, then tumbled by 36.34% to $946000.0 in 2023, then tumbled by 61.1% to $368000.0 in 2024, then decreased by 12.77% to $321000.0 in 2025, then sank by 34.27% to $211000.0 in 2026.
- Business Quant data shows BTAI's Interest & Investment Income at $211000.0 in Q1 2026, $321000.0 in Q4 2025, and $236000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.93 Mn | 24.93 Mn | 160,000.00 | 131,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 131,000.00 |
| Mar 31, 2026 | 211,000.00 |
| Dec 31, 2025 | 321,000.00 |
| Sep 30, 2025 | 236,000.00 |
| Jun 30, 2025 | 230,000.00 |
| Mar 31, 2025 | 279,000.00 |
| Dec 31, 2024 | 368,000.00 |
| Sep 30, 2024 | 616,000.00 |
| Jun 30, 2024 | 671,000.00 |
| Mar 31, 2024 | 947,000.00 |
| Dec 31, 2023 | 946,000.00 |
| Sep 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Mar 31, 2023 | 2.02 Mn |
| Dec 31, 2022 | 1.49 Mn |
| Sep 30, 2022 | 823,000.00 |
| Jun 30, 2022 | 204,000.00 |
| Mar 31, 2022 | 15,000.00 |
| Dec 31, 2021 | 12,000.00 |
| Sep 30, 2021 | 12,000.00 |